Table 1.
Clinical and pathological information
| Clinical data at time of biopsy |
Biopsy Findings |
Post Biopsy |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case No. | Age Onset SLE | Sex | Duration disease (Yrs) | Yr Bx | Age (Yrs) | anti DNA titer (<10) | C3 (83-177) | C4 (16-47) | CH50 (60-144) | Serum creat. (1.0-1.2) | Ur Pr | ISN/RPS Class | AI | CI | TBM Dep | Therapy | Follow up (yrs) | Final Outcome Status |
| 1 | 48 | M | 5 | 2007 | 51 | 48 | 12 | 122 | 2.7 | 4 | V | 1 | 2 | 0 | MMF+Pred | 3 | 2 | |
| 2 | 24 | F | 19 | 2007 | 40 | 9766 | 48 | 9 | 60 | 0.9 | 3 | IV-G & V | 18 | 3 | + | Imuran+Pred | ||
| 2 | 24 | F | 19 | 2008 | 41 | 754 | 42 | 16 | 45 | 3.3 | 3 | IV-G & V | 6 | 10 | + | CTX,MMF+Pred | 4 | 3 |
| 3 | 32 | F | 8 | 2004 | 32 | 2087 | 38 | 3 | 3 | 1.5 | 3 | III & V | 6 | 2 | + | MMF+Pred | ||
| 3 | 32 | F | 8 | 2007 | 36 | 872 | 64 | 9 | 24 | 1.9 | 2 | IV-S | 17 | 3 | + | CTX,MMF+Pred | 7 | 2 |
| 4 | 21 | M | 5 | 2006 | 22 | 3153 | 37 | 11 | 19 | 0.6 | 2 | IV-S | 8 | 0 | 0 | MMF+CSA+Pred | 4 | 0 |
| 5 | 33 | F | 16 | 2005 | 44 | 1770 | 53 | 20 | 93 | 0.8 | 3 | III & V | 6 | 3 | + | MMF+Pred | 5 | 0 |
| 6 | 20 | F | 7 | 2006 | 23 | 1513 | 32 | 5 | 1.6 | 2 | III & V | 3 | 7 | + | Imuran+Pred | 5 | 2 | |
| 7 | 11 | F | 16 | 2003 | 19 | 185 | 47 | 6 | 38 | 1.2 | 3 | III & V | 3 | 6 | + | CTX+Pred+CSA | ||
| 7 | 11 | F | 16 | 2005 | 21 | 14 | 59 | 13 | 1.3 | 2 | III & V | 3 | 9 | + | CTX+Rituximab,MMF | 4 | 1 | |
| 8 | 8.5 | F | 9.5 | 2003 | 11 | 17026 | 33 | 5 | 8 | 0.5 | 3 | IV-G & V | 18 | 3 | + | CTX,MMF+Pred | 8 | 0 |
| 9 | 20 | F | 7 | 2006 | 22 | 456 | 98 | 19 | 117 | 2.3 | 3 | III & V | 8 | 4 | + | CTX,MMF+Pred | 3 | 1 |
| 10 | 42 | F | 12 | 2006 | 49 | 1919 | 51 | 9 | 56 | 1.8 | 3 | IV-S | 12 | 6 | + | CTX+Pred | 5 | 1 |
| 11 | 14 | M | 5 | 2007 | 15 | 7 | 52 | 6 | 49 | 0.7 | 3 | III & V | 6 | 0 | 0 | CTX+Pred | 4 | 0 |
| 12 | 36 | F | 7 | 2005 | 37 | 1346 | 60 | 11 | 1.7 | 3 | V | 1 | 2 | 0 | CTX,MMF+Pred | 5 | 0 | |
| 13 | 17 | F | 12 | 2004 | 20 | 9216 | 40 | 6 | 0 | 0.6 | 1 | IV-G & V | 12 | 1 | 0 | MMF+Pred | ||
| 13 | 17 | F | 12 | 2004 | 22 | 2180 | 44 | 6 | 22 | 0.8 | 3 | IV-G & V | 15 | 4 | + | Imuran+Pred,CTX | ||
| 13 | 17 | F | 12 | 2005 | 23 | 903 | 103 | 25 | 67 | 1.2 | 3 | IV-G & V | 14 | 5 | 0 | MMF+Rituximab | ||
| 13 | 17 | F | 12 | 2008 | 26 | 46 | 53 | 18 | 147 | 5.2 | 3 | IV-G & V | 9 | 9 | 0 | MMF+Pred | 9 | 3 |
| 14 | 17 | F | 6 | 2007 | 19 | 376 | 54 | 7 | 86 | 2.7 | 3 | IV-S & V | 7 | 9 | + | Pred | 3 | 1 |
| 15 | 20 | F | 13 | 2006 | 29 | 180 | 66 | 13 | 36 | 2 | 3 | IV-G & V | 13 | 3 | 0 | CTX,MMF+Pred | ||
| 15 | 20 | F | 13 | 2009 | 32 | 11 | 91 | 28 | 157 | 5.4 | 2 | IV-G & V | 6 | 11 | 1 | MMF+Pred | 5 | 3 |
| 16 | 12 | M | 14 | 2002 | 17 | 1027 | 65 | 6 | 91 | 0.8 | 1 | IV-S | 8 | 2 | + | CTX+Pred | 3 | 0 |
| 17 | 20 | F | 7 | 2006 | 22 | 0.5 | 2 | III | 4 | 0 | + | Pred | 1 | |||||
| 17 | 20 | F | 7 | 2007 | 23 | 155 | 52 | 3 | 0.5 | 3 | IV-G & V | 13 | 3 | + | MMF+Pred | 0 | N/A | |
Duration disease (Yrs) to present; Serum creat.=serum creatinine mg/dl;Ur Pr=Urinary Protein, 0-4+; AI,CI= activity and chronicity indices; TBM dep=Tubular-basement membrane Ig deposits; CTX=cyclophosphamide; CSA=Cyclosporine; MMF=Mycophenolate mofetil; Pred=Prednisone; Final Outcome status, 0=normal renal function with persistent proteinuria, 1=serum creatinine elevated over U.L.N. ≥1.0mg/dl females, ≥1.2mg/dl males, but less than doubling, 2=doubling serum creatinine, 3 ESRD, S/P transplant, N/A not available.